San Raffaele Scientific Institute and EMO-GVM Centro Cuore, Columbus Hospital, Milan, Italy.
Circ Cardiovasc Interv. 2009 Oct;2(5):416-22. doi: 10.1161/CIRCINTERVENTIONS.109.886945. Epub 2009 Sep 22.
Limited long-term data exist on patients who have undergone drug-eluting stenting of very long lesions (requiring >or=60 mm of continuous stent) in native coronary arteries ("full-metal jacket").
We examined consecutive procedures taking place between March 2002 and 2007 at 2 high-volume centers in Milan, Italy. Exclusion criteria were percutaneous coronary intervention for restenosis, percutaneous coronary intervention to a bypass graft, or percutaneous coronary intervention for acute ST-elevation myocardial infarction (MI). We identified 658 full-metal jacket lesions in 617 patients. Average age of the cohort was 62.0+/-10.6; 32.8% were diabetic, 51.5% had a previous MI, and 33.4% had undergone a previous percutaneous transluminal coronary angioplasty. Mean ejection fraction was 52.1+/-10.4%. The lesion was a chronic total occlusion in 33.0%. Median duration of clinical follow-up was 39 months (interquartile range, 28 to 50). Six-month follow-up was achieved in 97% of patients; 2-year follow-up was achieved in 91%. All-cause mortality rate was 7.3%; cardiac death rate was 3.6%. Non-procedure-related MI rates were 3.5%. Target lesion revascularization rates were 23.4%. There were 17 cases of Academic Research Consortium-defined definite or probable stent thrombosis (2.6%): 5 acute, 2 subacute, 6 late, and 4 very late. Ten of the 17 cases occurred while the patient was receiving dual antiplatelet therapy; 4 of the 17 after premature termination of 1 or both antiplatelets, and 3 of the 17 occurred while the patient was receiving single-antiplatelet therapy, after having completed the prescribed course of dual antiplatelet therapy.
When very long lesions (>or=60 mm) were treated using overlapping drug-eluting stents, 23.4% required a further procedure for restenosis at 3-year follow-up. However, MI, stent thrombosis, and cardiac mortality rates were relatively low.
在意大利米兰的 2 个高容量中心,我们研究了 2002 年 3 月至 2007 年间连续进行的程序。排除标准为经皮冠状动脉介入治疗后再狭窄、经皮冠状动脉介入治疗旁路移植术或经皮冠状动脉介入治疗急性 ST 段抬高型心肌梗死(MI)。我们在 617 例患者中发现了 658 例全金属护套病变。队列的平均年龄为 62.0+/-10.6;32.8%为糖尿病患者,51.5%有心肌梗死史,33.4%有经皮腔内冠状动脉成形术史。平均射血分数为 52.1+/-10.4%。病变为慢性完全闭塞的占 33.0%。中位临床随访时间为 39 个月(四分位距,28 至 50)。97%的患者获得了 6 个月的随访;91%的患者获得了 2 年的随访。全因死亡率为 7.3%;心脏死亡率为 3.6%。非手术相关的 MI 发生率为 3.5%。靶病变血运重建率为 23.4%。发生了 17 例(2.6%)学术研究联合会定义的明确或可能的支架血栓形成:5 例急性,2 例亚急性,6 例晚期,4 例极晚期。在 17 例中有 10 例发生在患者接受双联抗血小板治疗期间;7 例发生在双联抗血小板治疗过早停药(1 种或 2 种)后;在完成双联抗血小板治疗规定疗程后,3 例发生在患者接受单联抗血小板治疗期间。
当使用重叠药物洗脱支架治疗>or=60 mm 的长病变时,3 年随访时 23.4%的患者需要进一步进行再狭窄治疗。然而,MI、支架血栓形成和心脏死亡率相对较低。